Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 1150 citing articles:

SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients
Maxime Taquet, Rebecca Sillett, Lena Zhu, et al.
The Lancet Psychiatry (2022) Vol. 9, Iss. 10, pp. 815-827
Open Access | Times Cited: 533
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression
Niklas Bobrovitz, Harriet Ware, Xiaomeng Ma, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 5, pp. 556-567
Open Access | Times Cited: 469
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California
Joseph A. Lewnard, Vennis Hong, Manish M. Patel, et al.
Nature Medicine (2022) Vol. 28, Iss. 9, pp. 1933-1943
Open Access | Times Cited: 321
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
Martina McMenamin, Joshua Nealon, Yun Lin, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 10, pp. 1435-1443
Open Access | Times Cited: 315
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Caroline Stein, Hasan Nassereldine, Reed J D Sorensen, et al.
The Lancet (2023) Vol. 401, Iss. 10379, pp. 833-842
Open Access | Times Cited: 306
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet (2022) Vol. 400, Iss. 10359, pp. 1213-1222
Open Access | Times Cited: 243
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Alessandro Sette, Shane Crotty
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 27-46
Open Access | Times Cited: 214
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
Nana Wu, Keven Joyal‐Desmarais, Paula Aver Bretanha Ribeiro, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 5, pp. 439-452
Open Access | Times Cited: 187
Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study
Waasila Jassat, Salim S. Abdool Karim, Caroline Mudara, et al.
The Lancet Global Health (2022) Vol. 10, Iss. 7, pp. e961-e969
Open Access | Times Cited: 184
Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study
Isobel Ward, Charlotte Bermingham, Daniel Ayoubkhani, et al.
BMJ (2022), pp. e070695-e070695
Open Access | Times Cited: 156
The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity
Yongbing Zhou, Hui‐Lin Zhi, Yong Teng
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 132
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
Julia Stowe, Nick Andrews, Freja Kirsebom, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 130
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study
Mie Agermose Gram, Hanne‐Dorthe Emborg, Astrid Blicher Schelde, et al.
PLoS Medicine (2022) Vol. 19, Iss. 9, pp. e1003992-e1003992
Open Access | Times Cited: 127
Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom
Catherine Hyams, Robert Challen, Robin Marlow, et al.
The Lancet Regional Health - Europe (2022) Vol. 25, pp. 100556-100556
Open Access | Times Cited: 124
Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study
José Villar, Constanza P. Soto Conti, Robert B. Gunier, et al.
The Lancet (2023) Vol. 401, Iss. 10375, pp. 447-457
Open Access | Times Cited: 122
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 6, pp. 387-397
Open Access | Times Cited: 119
Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022
Yonatan M. Mefsin, Dongxuan Chen, Helen S. Bond, et al.
Emerging infectious diseases (2022) Vol. 28, Iss. 9, pp. 1856-1858
Open Access | Times Cited: 119
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 8, pp. 1403-1411
Open Access | Times Cited: 116
COVID-19, Myocarditis and Pericarditis
DeLisa Fairweather, Danielle J. Beetler, Damian N. Di Florio, et al.
Circulation Research (2023) Vol. 132, Iss. 10, pp. 1302-1319
Open Access | Times Cited: 112
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022
Chiara Sacco, Martina Del Manso, Alberto Mateo‐Urdiales, et al.
The Lancet (2022) Vol. 400, Iss. 10346, pp. 97-103
Open Access | Times Cited: 110
Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England
Paul Elliott, Oliver Eales, Nicholas Steyn, et al.
Science (2022) Vol. 376, Iss. 6600
Open Access | Times Cited: 103
Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US
Seth Flaxman, Charles A. Whittaker, Elizaveta Semenova, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253590-e2253590
Open Access | Times Cited: 99
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark
Christian Holm Hansen, Nikolaj Ulrik Friis, Peter Bager, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 2, pp. 167-176
Open Access | Times Cited: 98
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study
Neil Krishan Aggarwal, Kyle C. Molina, Laurel Beaty, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 696-705
Open Access | Times Cited: 98
Page 1 - Next Page

Scroll to top